Cargando…
Implications of Pharmacogenetic Testing for Clopidogrel Therapy in a Tertiary Healthcare Hospital in North India
Background Clopidogrel hyporesponsiveness with decreased antiplatelet activity is prevalent in percutaneous coronary intervention (PCI) patients due to reduced function polymorphism in the CYP2C19 enzyme gene which results in poor conversion of this prodrug to an active metabolite. However, pharmaco...
Autores principales: | Amarapalli, Jayachandra, Sharma, Prabhat, Datta, Rajat, Sharma, Anuka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439363/ https://www.ncbi.nlm.nih.gov/pubmed/37602077 http://dx.doi.org/10.7759/cureus.42169 |
Ejemplares similares
-
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
por: Dahl, Marja-Liisa, et al.
Publicado: (2010) -
An Examination of Clopidogrel in the Treatment of Coronary Microvascular Disease
por: Iskandar, Nicholas P, et al.
Publicado: (2022) -
A Case of Hypoglycemia With Concomitant Use of a Sulfonylurea and Clopidogrel
por: Ruiz, Brent, et al.
Publicado: (2022) -
Cytochrome P450 2C19 Polymorphisms and Its Association With Major Adverse Cardiac Events in Post-coronary Intervention Patients on Clopidogrel in the Tertiary Care Center
por: Kambhampati, Nikhil Teja, et al.
Publicado: (2023) -
Acute Multiple In-Stent Thromboses in a Patient With Clopidogrel-Fluconazole Interaction
por: El Khoury, Antoine, et al.
Publicado: (2022)